Hypophysitis represents the most frequent endocrinopathy with anti-cytotoxic T lymphocyte antigen (CTLA-4) treatment (up to 15-20%) (4-7) while the prevalence is extremely lower (<1%) with anti-PD-1 and anti-PD-L1 therapy (3). Here, CTLA4 is linked to hypophysitis.